Has the targeted drug capmatinib been launched in China?

Capmatinib is a targeted drug used to treat metastatic non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. The drug has been successfully launched in China and has been included in the medical insurance system. Capmatinib, as a targeted therapy drug, has shown good efficacy in the treatment of patients with this type of lung cancer, providing patients with new treatment options and hope. Nonetheless, because capmatinib has been on the market for a relatively short time in China, patients may encounter certain difficulties when purchasing it.

Currently, the supply of capmatinib in domestic pharmacies is not stable, and patients in some areas may face drug shortages. For patients who urgently need the drug, it may be difficult to purchase it directly from China. In order to ensure timely access to treatment, some patients choose to purchase capmatinib through overseas channels, especially from some drug suppliers and cross-border e-commerce platforms.

In overseas markets, capmatinib mainly has two versions: original drug and generic version. The original drug capmatinib abroad is relatively expensive, usually tens of thousands of yuan, and the price varies by region and pharmacy. This price may be a significant financial burden for some patients, especially if long-term use is required. Despite this, patients can relieve some of their financial pressure through medical insurance reimbursement, but the specific reimbursement ratio and conditions may vary by region, so you need to consult the local hospital pharmacy.

Compared with the original drug, the generic version of capmatinib provides a more economical option. For example, the price of generic capmatinib produced in Laos is only more than 2,000 yuan, and its drug ingredients are basically the same as the original drug. For patients, this is undoubtedly a more people-friendly option, which can significantly reduce financial pressure while ensuring the treatment effect. Therefore, overseas generic drugs have received widespread attention and application in the market, becoming the first choice for many patients.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib